• Explore /
  • Poster
  • / JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.

JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.

Abstract Poster

Authors

null

David Michael Hyman

Memorial Sloan Kettering Cancer Center, New York, NY

David Michael Hyman , Amelia B. Zelnak , Todd Michael Bauer , Susanna Varkey Ulahannan , James M. Ford , Rossano Cesari , Margaret Hoyle , Colombe Chappey , Ross Stewart , Umberto Conte , Timothy A Yap

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03565991

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS2660)

DOI

10.1200/JCO.2019.37.15_suppl.TPS2660

Abstract #

TPS2660

Poster Bd #

296a

Abstract Disclosures

Similar Posters

First Author: Johann S. De Bono

First Author: Wassim Abida

First Author: Ruben Raychaudhuri

First Author: Vivek Narayan